Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shunichiro Iwasawa

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Oncotargets and Therapy|February 29, 2020
ALK Rearrangement Adenocarcinoma with Histological Transformation to Squamous Cell Carcinoma Resistant to Alectinib and CeritinibTaisuke Kaiho, Takahiro Nakajima, Shunichiro Iwasawa, et al.
World Journal of Clinical Oncology|October 11, 2014
Chronic obstructive pulmonary disease as a risk factor for lung cancerYuichi Takiguchi, Ikuo Sekine, Shunichiro Iwasawa, et al.
Advances in Therapy|July 12, 2024
A DPC Database Study on the Safety of Atezolizumab/Carboplatin/Etoposide in Extensive-Disease Small Cell Lung Cancer in Japanese PatientsMotohiro Tamiya, Shunichiro Iwasawa, Yusuke Sasaki, et al.
Advances in Therapy|July 11, 2024
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese PatientsAkito Hata, Shunichiro Iwasawa, Yusuke Sasaki, et al.
Japanese Journal of Clinical Oncology|May 14, 2014
Current status of medical oncology in Japan--reality gleaned from a questionnaire sent to designated cancer care hospitalsYuichi Takiguchi, Ikuo Sekine, Shunichiro Iwasawa, et al.
Oncology Reports|January 6, 2011
Upregulation of thioredoxin reductase 1 in human oral squamous cell carcinomaShunichiro Iwasawa, Yukio Yamano, Yuichi Takiguchi, et al.
Plos One|August 14, 2015
Crizotinib-Induced Abnormal Signal Processing in the RetinaToshiyuki Ishii, Shunichiro Iwasawa, Ryota Kurimoto, et al.
Oncology Letters|July 12, 2017
Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinomaRyota Kurimoto, Takahiro Ebata, Shunichiro Iwasawa, et al.
Oncology Reports|January 13, 2018
Inhibition of Gli leads to antitumor growth and enhancement of cisplatin-induced cytotoxicity in large cell neuroendocrine carcinoma of the lungTsukasa Ishiwata, Shunichiro Iwasawa, Takahiro Ebata, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 6, 2021
Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agentsGo Saito, Takahiro Ebata, Tsukasa Ishiwata, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Oncotargets and Therapy|February 29, 2020
ALK Rearrangement Adenocarcinoma with Histological Transformation to Squamous Cell Carcinoma Resistant to Alectinib and CeritinibTaisuke Kaiho, Takahiro Nakajima, Shunichiro Iwasawa, et al.
World Journal of Clinical Oncology|October 11, 2014
Chronic obstructive pulmonary disease as a risk factor for lung cancerYuichi Takiguchi, Ikuo Sekine, Shunichiro Iwasawa, et al.
Advances in Therapy|July 12, 2024
A DPC Database Study on the Safety of Atezolizumab/Carboplatin/Etoposide in Extensive-Disease Small Cell Lung Cancer in Japanese PatientsMotohiro Tamiya, Shunichiro Iwasawa, Yusuke Sasaki, et al.
Advances in Therapy|July 11, 2024
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese PatientsAkito Hata, Shunichiro Iwasawa, Yusuke Sasaki, et al.
Japanese Journal of Clinical Oncology|May 14, 2014
Current status of medical oncology in Japan--reality gleaned from a questionnaire sent to designated cancer care hospitalsYuichi Takiguchi, Ikuo Sekine, Shunichiro Iwasawa, et al.
Oncology Reports|January 6, 2011
Upregulation of thioredoxin reductase 1 in human oral squamous cell carcinomaShunichiro Iwasawa, Yukio Yamano, Yuichi Takiguchi, et al.
Plos One|August 14, 2015
Crizotinib-Induced Abnormal Signal Processing in the RetinaToshiyuki Ishii, Shunichiro Iwasawa, Ryota Kurimoto, et al.
Oncology Letters|July 12, 2017
Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinomaRyota Kurimoto, Takahiro Ebata, Shunichiro Iwasawa, et al.
Oncology Reports|January 13, 2018
Inhibition of Gli leads to antitumor growth and enhancement of cisplatin-induced cytotoxicity in large cell neuroendocrine carcinoma of the lungTsukasa Ishiwata, Shunichiro Iwasawa, Takahiro Ebata, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 6, 2021
Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agentsGo Saito, Takahiro Ebata, Tsukasa Ishiwata, et al.
Pageof 6